BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 21541039)

  • 1. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
    Ween MP; Oehler MK; Ricciardelli C
    Int J Mol Sci; 2011 Jan; 12(2):1009-29. PubMed ID: 21541039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Versican/PG-M Assembles Hyaluronan into Extracellular Matrix and Inhibits CD44-mediated Signaling toward Premature Senescence in Embryonic Fibroblasts.
    Suwan K; Choocheep K; Hatano S; Kongtawelert P; Kimata K; Watanabe H
    J Biol Chem; 2009 Mar; 284(13):8596-604. PubMed ID: 19164294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides.
    Ween MP; Hummitzsch K; Rodgers RJ; Oehler MK; Ricciardelli C
    Clin Exp Metastasis; 2011 Feb; 28(2):113-25. PubMed ID: 21153687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling.
    Hernández D; Miquel-Serra L; Docampo MJ; Marco-Ramell A; Cabrera J; Fabra A; Bassols A
    J Biol Chem; 2011 Jan; 286(2):1475-85. PubMed ID: 21078678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
    Serafino A; Zonfrillo M; Andreola F; Psaila R; Mercuri L; Moroni N; Renier D; Campisi M; Secchieri C; Pierimarchi P
    Curr Cancer Drug Targets; 2011 Jun; 11(5):572-85. PubMed ID: 21486216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronan, CD44 and versican in epidermal keratinocyte tumours.
    Karvinen S; Kosma VM; Tammi MI; Tammi R
    Br J Dermatol; 2003 Jan; 148(1):86-94. PubMed ID: 12534600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids.
    Desjardins M; Xie J; Gurler H; Muralidhar GG; Sacks JD; Burdette JE; Barbolina MV
    J Ovarian Res; 2014; 7():70. PubMed ID: 24999371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis.
    Gardner MJ; Catterall JB; Jones LM; Turner GA
    Clin Exp Metastasis; 1996 Sep; 14(4):325-34. PubMed ID: 8878406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.
    Yeung TL; Leung CS; Wong KK; Samimi G; Thompson MS; Liu J; Zaid TM; Ghosh S; Birrer MJ; Mok SC
    Cancer Res; 2013 Aug; 73(16):5016-28. PubMed ID: 23824740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration.
    Evanko SP; Potter-Perigo S; Bollyky PL; Nepom GT; Wight TN
    Matrix Biol; 2012 Mar; 31(2):90-100. PubMed ID: 22155153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular matrix of ovarian tumors.
    Ricciardelli C; Rodgers RJ
    Semin Reprod Med; 2006 Sep; 24(4):270-82. PubMed ID: 16944424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.
    Ricciardelli C; Ween MP; Lokman NA; Tan IA; Pyragius CE; Oehler MK
    BMC Cancer; 2013 Oct; 13():476. PubMed ID: 24124770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane protein glycosylation and CD44 content in the adhesion of human ovarian cancer cells to hyaluronan.
    Catterall JB; Jones LM; Turner GA
    Clin Exp Metastasis; 1999; 17(7):583-91. PubMed ID: 10845557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative therapy of ovarian cancer based on overexpression of CD44 receptor.
    Bukowska B; Marczak A
    Ginekol Pol; 2015 May; 86(5):388-91. PubMed ID: 26117979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas.
    Afify AM; Ferguson AW; Davila RM; Werness BA
    Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):309-14. PubMed ID: 11759056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of ovarian cancer cells to immobilized hyaluronic acid.
    Catterall JB; Gardner MJ; Jones LM; Turner GA
    Glycoconj J; 1997 Nov; 14(7):867-9. PubMed ID: 9511993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
    Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
    Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.
    Auzenne E; Ghosh SC; Khodadadian M; Rivera B; Farquhar D; Price RE; Ravoori M; Kundra V; Freedman RS; Klostergaard J
    Neoplasia; 2007 Jun; 9(6):479-86. PubMed ID: 17603630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of versican and hyaluronan in melanocytic tumors of dogs.
    Docampo MJ; Rabanal RM; Miquel-Serra L; Hernández D; Domenzain C; Bassols A
    Am J Vet Res; 2007 Dec; 68(12):1376-85. PubMed ID: 18052744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronan and hyaluronan binding proteins are normal components of mouse pancreatic islets and are differentially expressed by islet endocrine cell types.
    Hull RL; Johnson PY; Braun KR; Day AJ; Wight TN
    J Histochem Cytochem; 2012 Oct; 60(10):749-60. PubMed ID: 22821669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.